The increased popularity of GLP-1 receptor agonists, medications used for treating type 2 diabetes and weight loss, has brought attention to several potential health risks as regulators and medical experts call for greater awareness. Drugs like Wegovy, Ozempic, and Mounjaro have helped many patients manage their health, but recent studies and reports highlight rare but serious side effects, including acute pancreatitis and even cases of scurvy.
Health authorities in the United Kingdom recently updated their guidance for GLP-1 weight loss injections after noticing a rise in reports of acute pancreatitis, an inflammation of the pancreas. The Medicines and Healthcare Products Regulatory Agency (MHRA) responded to clusters of pancreatitis cases linked to these drugs. According to experts, although pancreatitis is an “uncommon” side effect—affecting about one in 100 users—it is serious. Symptoms include sudden abdominal pain, nausea, and swelling, and drug leaflets now warn patients to watch for these signs.
Medical specialists also point out that certain factors can increase the risk of pancreatitis in GLP-1 users. Patients who already have diabetes or obesity may have additional risks, such as gallstones or high triglycerides. Heavy alcohol use and a personal history of pancreatic disease may further raise the likelihood. While most people using GLP-1 medications face a low risk, experts advise patients to seek medical help if they notice severe abdominal pain, nausea, or persistent vomiting.
Other possible side effects of GLP-1 drugs include gastrointestinal issues like nausea, vomiting, diarrhea, and constipation. Some users have reported symptoms like medullary thyroid cancer risk, severe allergic reactions, and unusual brain fog, though these remain rare. Doctors recommend starting GLP-1 medications at low doses to minimize risk and increasing gradually, whether the drugs are used for diabetes or weight loss. They say the safety profile is generally favorable for people without pre-existing conditions.
A separate health concern tied to GLP-1 medications involves the risk of scurvy, a disease caused by vitamin C deficiency. With more people using these weight loss drugs, reports have surfaced of patients developing symptoms of scurvy, such as fatigue, joint pain, bleeding gums, and skin issues. Professor Clare Collins from Newcastle School of Health Sciences warns that the reduced food intake associated with GLP-1 drugs may lead to malnutrition if patients do not get enough essential nutrients, including vitamins and protein. Collins urges medical professionals to monitor patients closely, not just for weight and blood sugar, but also for overall nutrition, especially as GLP-1 options expand with newly approved pill forms.
Experts emphasize that while the risks associated with GLP-1 drugs are low, patients should be aware of symptoms and talk to their healthcare providers about any concerns. Drug regulators continue to monitor adverse reactions, and medical advice highlights the importance of balancing benefits and risks while ensuring that nutrition and overall health are not overlooked.
